Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that all resolutions have been duly passed by shareholders at the Annual General Meeting held today.
The full text of each resolution is set out in the Notice of Annual General Meeting, included in the 2020 Annual Report, which is available under the Investor Documents & Presentations section of the Company’s website www.avacta.com.
Given shareholders were advised not to attend the Annual General Meeting as a result of the Coronavirus pandemic and Government guidance, the Company would like to advise shareholders that the most recent business updates and presentations can be found under the Investor Documents & Presentations section of the Company’s website www.avacta.com.